Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Gastrointestinal Cancer Market from 2024 to 2025?

There has been a swift expansion in the market size of gastrointestinal cancer in the past few years. It is predicted to climb up from $24.09 billion in 2024 to $27.05 billion in 2025, progressing at a compound annual growth rate (CAGR) of 12.3%. The earlier growth phase can be linked to an increase in cases of gastrointestinal cancers, enhanced tobacco and alcohol usage, the rise in the elderly population, unhealthy eating habits, and progress in oncology diagnostic procedures and treatments.

What Is the Projected Market Size of the Gastrointestinal Cancer Market?

Achieving swift expansion in the coming years, the size of the gastrointestinal cancer market is projected to reach $42.45 billion by 2029, with a compound annual growth rate (CAGR) of 11.9%. The anticipated expansion during this forecast period is due in part to the growing preference for biomarker-driven therapies, an increase in consciousness regarding early screening, enhancements in healthcare infrastructure, government-driven programs for cancer support, and an amplified focus on minimally invasive techniques. The upcoming period will see a surge in trends like technological advancements related to diagnostic tools, innovative targeted therapies, breakthroughs in immunotherapy, the expanding use of artificial intelligence in treating cancer, along with continued research and development in the field of precision oncology.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24546&type=smp

Who are the Major Competitors in the Gastrointestinal Cancer Market Outlook?

Major companies operating in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Parexel International Corporation, Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, Taiho Pharmaceutical Co. Ltd.

What Is Fueling Growth in the Gastrointestinal Cancer Market?

The growing use of targeted therapies is set to stimulate the expansion of the market for gastrointestinal cancer. These specific treatments inhibit the growth of cancer cells by acting on particular molecular targets, thereby minimizing damage to healthy, normal cells. Targeted therapies are created to influence specific molecular pathways or genetic mutations responsible for a disease, particularly in cancer. Unlike conventional treatments like chemotherapy, which affect both healthy and diseased cells, targeted therapies concentrate on the unique features of a patient’s disease. These therapies for gastrointestinal (GI) cancer influence specific genes or proteins in charge of tumor growth, delivering accurate and efficient treatment. This leads to improved outcomes and fewer side effects compared to traditional chemotherapy. For example, in July 2023, as reported by the American Society of Gene & Cell Therapy (ASGCT), a professional membership organization based in the US, and Citeline, a US-based supplier of drugs and devices, there were 247 gene therapies in Phase II at the end of the first quarter (Q1) 2023. This number increased by 5% to 260 by the end of the second quarter (Q2). As such, the growing use of targeted therapies is fueling the expansion of the gastrointestinal cancer market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24546&type=smp

Which Gastrointestinal Cancer Market Segments Are Growing the Fastest?

The gastrointestinal cancer market covered in this report is segmented –

1) By Cancer Type: Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Other Cancer Types

2) By Diagnostics: Endoscopy, Biopsy, Molecular Diagnostics, Imaging, Other Diagnostics

3) By Treatment: Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery, Other Treatments

4) By End-User: Hospitals, Oncology Centers, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By Colorectal Cancer: Colon Cancer, Rectal Cancer, Recurrent Colorectal Cancer, Metastatic Colorectal Cancer

2) By Stomach Cancer: Adenocarcinoma, Gastrointestinal Stromal Tumors (GIST), Lymphoma, Carcinoid Tumors

3) By Esophageal Cancer: Adenocarcinoma, Squamous Cell Carcinoma, Small Cell Carcinoma, Other Rare Esophageal Tumors

4) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Endocrine (Neuroendocrine) Pancreatic Tumors, Metastatic Pancreatic Cancer, Resectable Or Unresectable Tumors

5) By Liver Cancer: Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma, Hepatoblastoma, Secondary (Metastatic) Liver Cancer

6) By Other Cancer Types: Small Intestine Cancer, Anal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor

Which Industry Trends Are Shaping the Future of the Gastrointestinal Cancer Market?

Key players in the gastrointestinal cancer market are concentrating their efforts on the creation of innovative solutions, such as monoclonal antibody therapy, to enhance patient’s survival rates and lessen the negative impacts of treatment. This therapy involves the utilization of lab-made antibodies that can accurately identify and attach to cancer cells, aiding the immune system in its detection and eradication of these cells. To illustrate, Astellas Pharma Inc., a pharmaceutical firm based in Japan, rolled out VYLOY (zolbetuximab) in conjunction with fluoropyrimidine- and platinum-centric chemotherapy in September 2024, after getting the green light from the European Commission. This is the initial line of treatment for adults suffering from advanced, non-surgical locally-advanced or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma, in which tumors express claudin 18.2 (CLDN18.2). This nod from the European Commission makes VYLOY the only therapy available in the European Union that targets CLDN18.2, a biomarker found in roughly 38% of these patients. This stat is based on the encouraging results seen in the SPOTLIGHT and GLOW clinical trials.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

Which Countries Are Leading the Gastrointestinal Cancer Market?

North America was the largest region in the gastrointestinal cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24546

This Report Delivers Insight On:

1. How big is the gastrointestinal cancer market, and how is it changing globally?

2. Who are the major companies in the gastrointestinal cancer market, and how are they performing?

3. What are the key opportunities and risks in the gastrointestinal cancer market right now?

4. Which products or customer segments are growing the most in the gastrointestinal cancer market?

5. What factors are helping or slowing down the growth of the gastrointestinal cancer market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model